Sweden's SciBase Q3 net sales rise on higher electrode volumes
Overview
Sweden medtech firm's Q3 net sales rose 41% yr/yr, driven by higher electrode volumes
Net loss widened in Q3, while loss per share improved due to higher share count
Gross margin improved to 72.3%, aided by production improvements despite currency and gold price impacts
Outlook
SciBase did not provide specific guidance for upcoming quarters or the full yr in the press release
Result Drivers
ELECTRODE SALES - Electrode sales volume increased by 36% and repeat sales to existing customers rose 40%
GEOGRAPHIC GROWTH - Sales in Germany skin cancer segment rose 18% vs Q2-25; US skin cancer sales up 68% and skin barrier segment up 286%
GROSS MARGIN FACTORS - Margin was negatively affected by currency and gold prices, and production ramp-up costs, but offset by production improvements
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | SEK 14.62 mln | ||
Q3 Loss Per Share | SEK 2.52 | ||
Q3 Net Loss | SEK 25.77 mln | ||
Q3 Gross Margin | 72.30% |
Analyst Coverage
Wall Street's median 12-month price target for SciBase Holding AB (publ) is SEK39.93, about 255% above its November 11 closing price of SEK11.25
Reuters Recommended Reads
Nov 12 - Germany's Stratec 9M sales fall, but cost cuts lift margins
Nov 12 - Medtech firm Ottobock Q3 revenue rises on B2B segment growth
Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)